Carl E. Allen, MD, PhD
Department or Service
- Texas Medical Center
Co-Director, Histiocytosis Program
Co-Director, Lymphoma Program
Associate Professor, Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine
|Baylor College of Medicine||fellowship||Pediatric Hematology Oncology||2008|
|Columbus Children's Hospital - Heart Center||residency||Pediatrics||2005|
|Ohio State University College of Medicine and Public Health||medical school||Doctor of Medicine||2002|
|Ohio State University College of Medicine and Public Health||university||Doctor of Philosophy|
About Carl Allen
Along with Dr. Kenneth McClain, Dr. Carl Allen has developed the largest Histiocytosis Center in the world with over 100 new diagnoses annually.
Dr. Allen graduated from Ohio State University College of Medicine and Public Health with his medical degree and doctorate of philosophy. He completed his resident at Columbus Children’s Hospital and pediatric hematology-oncology fellowship at Baylor College of Medicine.
His clinical special interests include: Langerhans cell histiocytosis (LCH), hemophagocytic lymphohistiocytosis (HLH), leukemia, lymphoma and stem cell transplantation. He is board certified by the American Board of Pediatrics in pediatric hematology/oncology.
|American Society for Pediatric Hematology/Oncology (ASPHO)||Member|
|American Society of Bone Marrow Transplantation (ASBMT)||Member|
|American Society of Clinical Oncology (ASCO)||Member|
|American Society of Hematology (ASH)||Member|
Dr. Carl Allen's primary research is focused on the clinical and biologic aspects of Langerhans cell histiocytosis (LCH). Along with Dr. Kenneth McClain, Dr. Carl Allen has developed the largest Histiocytosis Center in the world with over 100 new diagnoses annually, allowing the center to create a large bank of LCH tissues and plasma.
Dr. Allen has developed gene expression and proteomic strategies to analyze the identity and function of the cells that cause LCH. The ultimate goal of these experiments is to identify genes, proteins, and pathways that may be used to diagnose and cure patients with LCH. These experiments may also provide insight into dendritic cell biology and tumor immunology.
Dr. Carl Allen is an associate professor of pediatric hematology-oncology at Baylor College of Medicine (BCM). He is co-director of the Fayez Sarofim Lymphoma Program research laboratory at Texas Children's Cancer and Hematology Centers. Dr. Allen has significant experience in clinical as well as translational research. He is principal investigator of investigator-initiated clinical trials in Hodgkin lymphoma and non-Hodgkin lymphoma, both of which include correlative biology aims. He is national principal investigator of a study to optimize hematopoietic cell transplant in patients with EBV-related lymphoproliferative disorders, through the Blood and Marrow Transplant Clinical Trials Network.
Dr. Allen has an ongoing collaborative research effort with the Uganda Cancer Institute research program, and collects tissue (viably preserved tumor, peripheral blood cells and plasma) and linked clinical data on approximately 25 new endemic Burkitt's Lymphoma cases every quarter from Uganda.
Langerhans Cell Histiocytosis (LCH)
Hemophagocytic Lymphohistiocytosis (HLH)
Dendritic Cell Biology